ArticleEBioMedicine2018
Engineered Kidney Tubules for Modeling Patient-Specific Diseases and Drug Discovery.
Article in EBioMedicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 33 citations in OpenAlex.
- Kidney organoid models of polycystic kidney disease: challenges and future directions.American journal of physiology. Renal physiology · 2025Review
- PKD1 mutation perturbs morphogenesis in tubular epithelial organoids derived from human pluripotent stem cells.Scientific reports · 2025Article
- AI models for automated segmentation of engineered polycystic kidney tubules.Scientific reports · 2024Article
- Article
- Tubular injury in diabetic kidney disease: molecular mechanisms and potential therapeutic perspectives.Frontiers in endocrinology · 2023Review
- A protocol for the generation of EPO - Producing neural crest cells from human induced pluripotent stem cells.MethodsX · 2022Article
- Unravelling the Role of PAX2 Mutation in Human Focal Segmental Glomerulosclerosis.Biomedicines · 2021Article
- Current advances of stem cell-based therapy for kidney diseases.World journal of stem cells · 2021Review
- Human Pluripotent Stem-Cell-Derived Models as a Missing Link in Drug Discovery and Development.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Bioengineered Kidney Models: Methods and Functional Assessments.Function (Oxford, England) · 2021Review
- Multi-lineage Human iPSC-Derived Platforms for Disease Modeling and Drug Discovery.Cell stem cell · 2020Review
- Kidney Organoids as Disease Models: Strengths, Weaknesses and Perspectives.Frontiers in physiology · 2020Review
- Kidney organoids in translational medicine: Disease modeling and regenerative medicine.Developmental dynamics : an official publication of the American Association of Anatomists · 2020Review
- Effective reconstruction of functional organotypic kidney spheroid for in vitro nephrotoxicity studies.Scientific reports · 2019Article
- Growing a new human kidney.Kidney international · 2019Review
- Primary cardiac manifestation of autosomal dominant polycystic kidney disease revealed by patient induced pluripotent stem cell-derived cardiomyocytes.EBioMedicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The lack of engineering systems able to faithfully reproduce complex kidney structures in vitro has made it difficult to efficiently model kidney diseases and development. Using polydimethylsiloxane (PDMS) scaffolds and a kidney-derived cell line we developed a system to rapidly engineer custom-made 3D tubules with typical renal epithelial properties. This system was successfully employed to engineer patient-specific tubules, to model polycystic kidney disease (PKD) and test drug efficacy, and to identify a potential new pharmacological treatment. By optimizing our system we constructed functional ureteric bud (UB)-like tubules from human induced pluripotent stem cells (iPSCs), and identified a combination of growth factors that induces budding morphogenesis like embryonic kidneys do. Finally, we applied this assay to investigate budding defects in UB-like tubules derived from a patient with a PAX2 mutation. Our system enables the modeling of human kidney disease and development, drug testing and discovery, and lays the groundwork for engineering anatomically correct kidney tissues in vitro and developing personalized medicine applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.